Invaluable Study Provides Compelling Evidence for the Clinical Use of ALZpath Assay
SEPTEMBER 26, 2023
Dr. Therriault and their dedicated team have launched a preprint in The Lancet reporting on their essential study delving into the performance of pTau217 assays. The findings from this research strongly support the diagnostic excellence of the ALZpath pTau217 assay for identifying Alzheimer’s disease, and its robust association with amyloid-PET and tau-PET – the current clinical standards for Alzheimer’s pathology diagnosis.
Pivotal Study Reports Biological and Analytical Variation for pTau217
AUGUST 13, 2023
Dr. Wagner Brum and their exceptional team have illuminated the biological variation in leading blood-based biomarkers for Alzheimer’s disease, and found pTau217 has low individual biological variation compared to pTau181. We are honored that this study utilized our ALZpath pTau217 assay to determine the biological variation in pTau217.
ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch
JULY 18, 2023
ALZpath is proud to share that we have received funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate clinical availability of our blood based Alzheimer’s diagnostic test. This investment comes at a pivotal time as the first approval of a disease modifying therapy ushering in a new era in Alzheimer’s clinical care.
ALZpath to Present at AAIC Meeting
JULY 16-20, 2023
We are proud to share that we will join prominent researchers evaluating biomarkers for Alzheimer’s Disease that have utilized our cutting-edge pTau217 assay at the Alzheimer’s Association International Conference (AAIC) in Amsterdam. Follow the link below for a list of presentations of their important findings.
Breakthrough Study Reveals Diagnostic Power of ALZpath pTau217 Assay
JULY 12, 2023
The ALZpath pTau217 assay has been featured in a crucial evaluation of biomarkers of Alzheimer’s disease pathology. Dr. Nicholas Ashton and team demonstrated our ALZpath pTau217 assay can accurately identify and longitudinally monitor Alzheimer’s disease pathology, including in preclinical stages.
ALZpath Featured at AAN Meeting
APRIL 24, 2023
A recent study presented at the annual American Academy of Neurology (AAN) meeting found that the ALZpath pTau217 assay detected elevated pTau217 in Alzheimers Disease with the greatest fold difference for any assay evaluated. Further, the ALZpath pTau217 assay identified Alzheimer’s disease in mild cases, as well as moderate and severe.
Clinical Trials on Alzheimer Disease (CTAD)
DECEMBER 27, 2022
Plasma pTau217 has emerged as a promising biomarker for amyloid plaques and neurofibrillary tangles in Alzheimer’s disease. Studies indicate it can accurately detect positive individuals and predict future decline. Blood draws for pTau217 may soon replace PET scans in clinical trials.
ALZpath Announces Novel Scalable Assay for pTau217
NOVEMBER 11, 2022
“ALZpath, Inc.”, an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated an Scalable Assay for Detection of Phosphorylated Tau 217 in Blood.
Alzheimer’s in the News
FDA approves first Alzheimer’s therapy shown to clearly slow cognitive decline
Stat news: JULY 6, 2023
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Lilly Investors News Release: May 3, 2023
Catalyst: Hope is on the Horizon for Alzheimer’s Treatments
The Stanford GSB Experience: March 10, 2023
MIND and Mediterranean Diets Associated with fewer Alzheimer's Plaques and Tangles
American Academy of Neurology: March 8, 2023